A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC — MAGELLAN

Metastatic Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

Official title:
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)

Status Active, not recruiting

Clinical Trial Summary

This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Description

This is a Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC). ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Metastatic Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details

NCT number	NCT03819465
Study type	Interventional
Source	AstraZeneca
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	December 27, 2018
Completion date	March 26, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03158883` - UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients	Early Phase 1
Withdrawn	`NCT04466917` - A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer	Phase 3
Recruiting	`NCT02622581` - Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients